Share

The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data: 
News in Numbers

Data: News in Numbers

$300m 

Bristol Myers Squibb takes on racial inequality with $300m pledge to up diversity, improve healthcare access.

10%  

The number of patients admitted for routine treatment in hospitals in England was down 67% in June compared with the same time last year, NHS figures show.

 67% 

190 million 

AstraZeneca joins other top flu vaccine players Sanofi, GlaxoSmithKline and Seqirus in efforts to boost flu vaccine manufacturing for the 2020-2021 season. Those companies plan to ship a combined 190 million doses.

$37 

Moderna has announced plans to charge between $32 to $37 per dose for its mRNA shot, dubbed mRNA-1273, for some “smaller-volume” purchasers.

86

New research from UC Berkeley and the University of Chicago found clear evidence of a drug dose gender gap for 86 different medications approved by the FDA.

Data: News in Numbers

$300m 

Bristol Myers Squibb takes on racial inequality with $300M pledge to up diversity, improve healthcare access.

67% 

The number of patients admitted for routine treatment in hospitals in England was down 67% in June compared with the same time last year, NHS figures show.

190 million  

AstraZeneca joins other top flu vaccine players Sanofi, GlaxoSmithKline and Seqirus in efforts to boost flu vaccine manufacturing for the 2020-2021 season. Those companies plan to ship a combined 190 million doses.

$37 

Moderna has announced plans to charge between $32 to $37 per dose for its mRNA shot, dubbed mRNA-1273, for some “smaller-volume” purchasers.

86 

New research from UC Berkeley and the University of Chicago found clear evidence of a drug dose gender gap for 86 different medications approved by the FDA.

 Study shows how viruses operate and evade the immune system

University of Otago researchers have learnt more about how viruses operate and can evade the immune system and are now using their discovery to help learn more about Covid-19.

Source: News Medical

 Russia skips ahead in COVID vaccine race, triggering outcry over unproven 'Sputnik V' shot

As global vaccine players rush to deliver Covid-19 vaccines, Russia shocked the world with news that it had approved a locally developed inoculation. But that approval was based on skimpy data, and experts characterised the move as a risky political stunt.

Source: Fierce Pharma

Italy becomes first country to require pharma to disclose public funding for R&D costs

Amid growing clamor for more transparency from the pharmaceutical industry, Italy has become the first country to require drug makers to disclose data about public funding for any of their medicines during negotiations over pricing and reimbursement.

Source: Stat News

  Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase alfa, setting up a possible approval by 27 January.

Source: Pharmaphorum

Approvals

 Cosentyx®

Novartis Cosentyx® receives EU approval for first-line systemic treatment in paediatric psoriasis.

Source: Pharmafield

Viltepso (viltolarsen)

The US FDA has granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Source: FDA

Evrysdi (risdiplam)

The US FDA has approved Evrysdi (risdiplam) for treatment of spinal muscular atrophy in adults and children aged two months and older.

Source: Roche

Rozlytrek 

Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation.

Source: Roche

Go to top

Share this article

Go to article: Home | Pause for thoughtGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: NewsGo to article: BaxterGo to article: Covid-19 executive briefing by GlobalDataGo to article: ELPRO Monitoring SolutionsGo to article: Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for successGo to article: Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19Go to article: FargoGo to article: Disruptions to global oncology trials have fallen to a three-month lowGo to article: MimotopesGo to article: AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cliGo to article: Biotech IPO valuation relies on data to enter capital markets during Covid-19 paGo to article: Nelson LabsGo to article: The pharma industry briefingGo to article: Pfeiffer VacuumGo to article: A century of cultures: celebrating the world’s oldest lab culture collectionGo to article: SkyepharmaGo to article: Gut feeling: exploring the therapeutic potential of the gut-brain axisGo to article: OptelGo to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debateGo to article: Air FranceGo to article: Debunking myths about puberty blockers for transgender childrenGo to article: MicronovaGo to article: Hiring from home: pharma recruitment in the age of Covid-19 Go to article: Nipro PharmapackagingGo to article: Q&A: breaking new ground in pharma packaging with HoneywellGo to article: WipotecGo to article: Treatment-resistant rare diseases: exploring landmark drug approvals in 2020Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Modernising pharma patents: can AI be an inventor?Go to article: ILC Dover Go to article: Boosting agility to accelerate project timescales Go to article: Scandinavian HealthGo to article: Doing the right thing: the enhanced case for complianceGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue